CUROCELL
Curocellโs OVISโข technology enhances immune cells to overcome immune suppression in tumor microenvironments.
CUROCELL
Industry:
Biopharma Biotechnology
Founded:
2016-01-01
Address:
Daejeon, Taejon-jikhalsi, South Korea
Country:
South Korea
Website Url:
http://www.curocellbtx.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Universal Analytics
Similar Organizations
Cellect Biotechnology
Cellect Biotechnology is a biotechnology company engaged in developing a novel technology platform.
Enzyvant Sciences
Enzyvant Sciences is a biotechnology company which focuses on developing treatments for rare diseases.
Official Site Inspections
http://www.curocellbtx.com
- Host name: 81.106.194.35.bc.googleusercontent.com
- IP address: 35.194.106.81
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Curocell"
ํ๋ก์ - ํ์ ์ ์ธ ํญ์๋ฉด์ญ์ธํฌ์น๋ฃ์ ๊ฐ๋ฐ์ ์ ๋์ฃผ์
๋ฉด์ญ์ธํฌ๋ฅผ ์ด์ฉํ ํญ์์ธํฌ ์น๋ฃ์ ๊ฐ๋ฐ ์ ๋ฌธ๊ธฐ์ ์ ๋๋ค. ์ฐจ๋ณํ๋ ๊ธฐ์ ๊ฐ๋ฐ๋ก ๋ณด๋ค ๋ง์ ํ์์๊ฒ ํฌ๋ง์ ์ฃผ๋ ๊ธฐ์ ์ผ๋ก ์ฑ์ฅํด ๋๊ฐ๊ณ ์์ต๋๋ค.See details»
About us - ํ๋ก์
Board of Directors๊น ๊ฑด ์๋ํ์ด์ฌ / ๊ณต๋์ฐฝ์ ์๊น ํ ์ฒ , Ph.D.์ฐ๊ตฌ๊ฐ๋ฐ์ผํฐ์ฅ / ์ ๋ฌด๋ฐ ์ง ๊ฒฝ์ฌ๋ฌด์ด์ฌ / ์๋ฌดํ ์ฐฝ ์์ฌ์ธ์ด์ฌ๊ฐ ํ์ฌ์ธ์ด์ฌ๊น ์ฉ ํ๊ฐ์ฌCo-founder์ฌ ํ ๋ณด, Ph.D.See details»
Curocell, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Www.curocellbtx.com. Public Company | 2016 | Daejeon, South Korea | 100-250 | KRX: 372320 | www.curocellbtx.com. Last update 01 Nov 2024. ... is a global contract research organization โฆSee details»
Curocell - Crunchbase Company Profile & Funding
Curocellโs OVISโข technology enhances immune cells to overcome immune suppression in tumor microenvironments.See details»
Curocell Inc. (KOSDAQ: 372320) Company Profile & Overview
Oct 2, 2024 Company profile for Curocell Inc. (KOSDAQ: 372320) with a description, list of executives, contact details and other key facts.See details»
Curocell - LinkedIn
Curocell is a cell therapy company that discovers and develops CAR-T therapies for cancer. The company's current efforts focus on unleashing the bodyโs immune system through broad-spectrum CAR-T ...See details»
Curocell - Overview, News & Similar companies | ZoomInfo.com
Curocell contact info: Phone number: +82 428633698 Website: www.curocellbtx.com What does Curocell do? Curocell, based in Daejeon, South Korea, is clinical-stage biotech innovating โฆSee details»
Curocell - Company Profile - Tracxn
Nov 27, 2024 Curocell - Developer of immune cell therapies. Raised a total funding of $82.4M over 4 rounds from 23 investors. Founded by Gunsoo Kim, Chan Hyuk Kim and 1 other in the โฆSee details»
ESG Management - ํ๋ก์ - curocellbtx.com
[email protected] Tel. / FAX 042-863-3698 / 042-863-3695 ์ ๋ณด ์ ํ . ์ดํด๊ด๊ณ ์ง๋ฌด์ ํํผ ...See details»
GEO Accession viewer - National Center for Biotechnology โฆ
Sep 28, 2022 [email protected]: Organization name: Curocell: Street address: 48, Yuseong-daero 1184beon-gil, Yuseong-gu: City: Daejeon: ZIP/Postal code: 34109: Country: โฆSee details»
Company Curocell Inc. - MarketScreener.com
Nov 30, 2016 Curocell Inc is a Korea-based company principally engaged in the manufacture, research and development (R&D) of drugs. The Company is also engaged in the development โฆSee details»
Curocell, Breaks Ground on 'CAR-T Manufacturing GMP Facility'
DAEJEON, South Korea, Dec. 23, 2021 Curocell, currently on Phaseโ CAR-T Therapy clinical trial with CRC01 (anbalcabtagene autoleucel) has recently broken ground...See details»
Curocell announced encouraging updates on the next-generation โฆ
Jun 20, 2023 84% ORR (32 of 38 patients) and 71% CR (27 of 38 patients) documented after 2 million cells/kg dose anbal-cel treatment to patients in relapsed/refractory large B-cell lymphomaSee details»
Curocell announced impressive CR rate in Phase 1 study with
Jun 13, 2022 Three (3) among 4 patients dosed at 2x10 5 cells/kg of anbal-cel documented complete remission, and 2 responding patients are maintaining the complete remission for โฆSee details»
Sciences - ํ๋ก์
OVISโข (OVercome Immune Suppression): Curocellโs proprietary platform technology to inhibit CAR-T cell exhaustionSee details»
Curocell, Inc. | Insights
Dec 6, 2023 Already A Biomedtracker Subscriber? You have access to the full company record through your subscription.See details»
Curocell announces Korean FDA clearance of the IND for CRC01, a โฆ
Feb 22, 2021 DAEJEON, South Korea, Feb. 2 2, 2021 /PRNewswire/ -- Curocell, Inc., a clinical-stage biotech developing next-generation CAR-T (OVIS โข) therapies, announced that the โฆSee details»
372320 Stock Price Quote - Morningstar
6 days ago See the latest Curocell Inc stock price (372320:XKRX), related news, valuation, dividends and more to help you make your investing decisions.See details»
Research programme: chimeric antigen receptor T cell therapies
If your organization has a subscription, there are several access options, even while working remotely: Working within your organizationโs network Login with username/password or try to โฆSee details»
Curocell announced encouraging updates on the next ... - ํ๋ด์ค
Jun 20, 2023 The anbal-cel is the next-generation OVIS TM technology applied to anti-CD19 CAR-T using the 4-1BB domain as a co-stimulation domain as and also it consists of a dual โฆSee details»